National Healthcare's 15min chart shows MACD Death Cross, bearish Marubozu pattern.

National Healthcare's 15-minute chart recently exhibited a MACD Death Cross, accompanied by a Bearish Marubozu candlestick pattern at 09:30 on September 24, 2025. This technical indicator suggests that the stock price may continue to decline, as sellers have taken control of the market and bearish momentum is likely to persist.

Viemed Healthcare Inc. (NASDAQ: VMD), a leading provider of home-based respiratory care solutions, has experienced notable financial growth and strategic acquisitions in recent quarters. The company reported strong Q2 2025 financial results, with record net revenues of $63.1 million, up 14.7% year-over-year. Net income reached $3.2 million ($0.08 per diluted share), a 115.1% increase from Q2 2024. The company's Adjusted EBITDA grew 11.5% to $14.3 million Viemed Healthcare Inc Stock Price, News & Analysis^[1].

Key highlights include significant patient growth, with ventilator patients up 11.4% to 12,152 and PAP therapy patients increasing 51.4% to 26,260. Additionally, Viemed completed a $26 million acquisition of Lehan's Medical Equipment on July 1, 2025, which generated $25.7 million in net revenues and $7.4 million in Adjusted EBITDA in 2024. The acquisition strengthens Viemed's presence in post-acute respiratory healthcare and expands its geographical footprint .

Technical indicators also provide insights into Viemed's stock performance. On September 24, 2025, the 15-minute chart of National Healthcare exhibited a MACD Death Cross, accompanied by a Bearish Marubozu candlestick pattern at 09:30. This suggests that the stock price may continue to decline, as sellers have taken control of the market and bearish momentum is likely to persist .

Despite the technical indicators, Viemed maintains a strong financial position with $20 million in cash and $55 million available in credit facilities. The company has raised its 2025 guidance, now expecting revenue between $271-277 million and Adjusted EBITDA of $59-62 million. CEO Casey Hoyt emphasized the company's confidence in its long-term outlook and commitment to shareholder value, supported by strong balance sheet and increasing free cash flow Viemed Healthcare Inc Stock Price, News & Analysis^[1].

Viemed has also completed its share repurchase program, authorizing the buyback of up to 1,976,441 common shares (5% of outstanding shares) through June 2026. The program was executed at a weighted average price of $6.69 per share, totaling approximately $13.2 million .